Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy: both recombinant TRAIL and monoclonal antibodies that target these receptors have entered clinical trials. How are these agents faring? What are the current stumbling blocks?
- Ricky W. Johnstone
- Ailsa J. Frew
- Mark J. Smyth